MDGL MADRIGAL PHARMACEUTICALS, INC.companySEC Filings & Insider Trading Activity 2026
Latest MADRIGAL PHARMACEUTICALS, INC. (MDGL) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 19, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on April 28, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for MADRIGAL PHARMACEUTICALS, INC. (MDGL) (SEC CIK 1157601), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: development and commercialization of pharmaceutical therapies for liver diseases, primarily noncirrhotic MASH
- • New product: Launch and full-year commercialization of Rezdiffra in U.S. (approved Mar 2024) and market entry in Germany (Sep 2025)
Risk Factors
- • Regulatory risk: accelerated approval of Rezdiffra under FDA Subpart H pathway contingent on completing MAESTRO-NASH trials for full approval
- • Geopolitical/macro risk: U.S. Medicare drug price negotiation program starting 2026 may cap prices and impose rebates on high-spend drugs like Rezdiffra
Management Discussion & Analysis
- • No revenue or YoY change figures provided in the MD&A
- • No profitability or margin percentages disclosed
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Revenue $287.3M Q3 2025 vs $62.2M Q3 2024, up 362% due to increased Rezdiffra demand
- • Operating loss stable: $(114.0)M Q3 2025 vs $(116.3)M Q3 2024, 2% improvement
Annual Reports Archive10-K
AI-powered analysis of MADRIGAL PHARMACEUTICALS, INC. (MDGL) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of MADRIGAL PHARMACEUTICALS, INC. (MDGL) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $0 | $0 | $180.1M | $958.4M |
| Operating Income | -$293.6M | -$380.5M | -$497.9M | -$300.1M |
| Net Income | -$295.4M | -$373.6M | -$465.9M | -$288.3M |
| Op. Margin | — | — | -276.4% | -31.3% |
| Net Margin | — | — | -258.6% | -30.1% |
| Balance Sheet | ||||
| Total Assets | $362.6M | $640.5M | $1.0B | $1.3B |
| Equity | $197.4M | $405.3M | $754.4M | $602.7M |
| ROE | -149.6% | -92.2% | -61.8% | -47.8% |
Source: XBRL financial data from MADRIGAL PHARMACEUTICALS, INC. (MDGL) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 28, 2026 | — | — | — |
8-K | Feb 19, 2026 | — | — | |
10-K | Feb 19, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 30, 2026 | — | — | |
8-K | Dec 11, 2025 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 1, 2025 | Mar 31, 2025 | — | |
10-K | Feb 26, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Feb 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Feb 24, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Feb 25, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest MDGL SEC filings in 2026?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did MDGL file its most recent 10-K annual report?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view MDGL 10-Q quarterly reports?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every MDGL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has MDGL filed recently?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find MDGL insider trading activity (Form 4)?
SignalX aggregates every MDGL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does MDGL file with the SEC?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MDGL filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
What is MDGL's SEC CIK number?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s SEC CIK (Central Index Key) number is 1157601. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1157601 to look up all MDGL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find MDGL return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from MADRIGAL PHARMACEUTICALS, INC. (MDGL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of MADRIGAL PHARMACEUTICALS, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 69+ filings.